| 2025-11-20 |
详情>>
内部人交易：
Rosenblum Mark J股份增加20000.00股
|
| 2025-11-14 |
详情>>
股本变动：
变动后总股本586.22万股
变动原因 ▼▲
- 原因：
- Common Stock offered 2,514,335 shares by the company
|
| 2025-11-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-14.35美元,归母净利润-354.08万美元,同比去年增长13.89%
|
| 2025-11-07 |
股东大会：
将于2025-12-19召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors to our Board of Directors (our “Board”), each to serve until our 2028 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified (“Proposal 1”).
2.To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in the attached proxy statement (“Proposal 2”).
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 (“Proposal 3”).
4.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.
|
| 2025-08-16 |
复牌提示：
2025-08-15 19:50:00 停牌，复牌日期 2025-08-18 09:00:00
|
| 2025-08-14 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益-1.41美元,归母净利润-266.74万美元,同比去年增长15.04%
|
| 2025-05-27 |
股东大会：
将于2025-07-08召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s outstanding shares of common stock at a ratio in the range of 1:4 to 1:40, as determined by the Company’s Board of Directors (the “Board”), and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board in its sole discretion (the “Reverse Stock Split Proposal”).
2.To approve, for purposes of complying with Nasdaq Listing Rules 5635(a) and 5635(d), the issuance of shares of the Company's common stock pursuant to that certain securities purchase agreement, dated December 12, 2024 (the “Purchase Agreement”), by and between the Company and C/M Capital Master Fund, LP, without giving effect to the exchange cap in the Purchase Agreement (the “Nasdaq 20% Issuance Proposal”).
3.To approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve the Reverse Stock Split Proposal and/or the Nasdaq 20% Issuance Proposal (the “Adjournment Proposal”).
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-1.03美元,归母净利润-170.95万美元,同比去年增长0.34%
|
| 2025-03-21 |
详情>>
业绩披露：
2024年年报每股收益-5.79美元,归母净利润-557.58万美元,同比去年增长55.55%
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-5.13美元,归母净利润-411.18万美元,同比去年增长64.74%
|
| 2024-11-01 |
股东大会：
将于2024-12-20召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors to our Board of Directors (our “Board”), each to serve until our 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
2.To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in the attached proxy statement.
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
4.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.
|
| 2024-08-09 |
详情>>
业绩披露：
2024年中报每股收益-5.62美元,归母净利润-313.97万美元,同比去年增长65.94%
|
| 2024-06-17 |
详情>>
拆分方案：
每8.0000合并分成1.0000股
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.41美元,归母净利润-171.53万美元,同比去年增长67.88%
|
| 2024-03-26 |
股东大会：
将于2024-05-09召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s outstanding shares of common stock at a ratio in the range of 1:4 to 1:8, as determined by the Company’s Board of Directors (the “Board”), and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board in its sole discretion (the “Reverse Stock Split Proposal”).
2.To approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve the Reverse Stock Split Proposal (the “Adjournment Proposal”).
|
| 2024-03-22 |
详情>>
业绩披露：
2023年年报每股收益-3.84美元,归母净利润-1254.27万美元,同比去年增长60.32%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.84美元,归母净利润-1166.09万美元,同比去年增长53.79%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-3.45美元,归母净利润-921.81万美元,同比去年增长14.86%
|
| 2023-05-01 |
股东大会：
将于2023-06-14召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors to our Board of Directors (our “Board”), each to serve until our 2026 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
2.To approve the Amended and Restated Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan.
3.To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in the attached Proxy Statement.
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
5.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.
|
| 2022-10-17 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2022-08-05 |
财报披露：
美东时间 2022-08-05 盘后发布财报
|
| 2022-04-28 |
股东大会：
将于2022-06-15召开股东大会
会议内容 ▼▲
- 1.elect two Class I directors, Arnold Hanish and William McVicar and, to serve until the 2025 annual meeting of stockholders or until their respective successors are duly elected and qualified;
2.to approve an amendment to our amended and restated certificate of incorporation to effect a reverse stock split of our common stock;
3.approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in the attached Proxy Statement;
4.ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
5.transact such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-27 |
股东大会：
将于2021-06-16召开股东大会
会议内容 ▼▲
- 1.elect two Class III directors, Tess Burleson and Paul Lammers and, to serve until the 2024 annual meeting of stockholders or until their respective successors are duly elected and qualified;
2.approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in the attached Proxy Statement;
3.ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.approve, on a non-binding advisory basis, the frequency of holding an advisory vote and named executive officer compensation;
5.transact such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.
|
| 2020-04-29 |
股东大会：
将于2020-06-19召开股东大会
会议内容 ▼▲
- 1.Elect three Class II directors, David J. Arthur, Bruce J. McCreedy and Jonathan Lieber;
2.Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.Approve the amended and restated 2015 Equity Incentive Plan;
4.Approve the amended and restated 2015 Employee Stock Purchase Plan;
5.such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.
|
| 2019-09-18 |
股东大会：
将于2019-10-21召开股东大会
会议内容 ▼▲
- 1.to elect the Board of Director’s two nominees for directors to hold office until the 2022 Annual Meeting of Stockholders;
2.to ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019;
3.to conduct any other business properly brought before the meeting.
|
| 2019-07-22 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2018-04-23 |
股东大会：
将于2018-06-06召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s one nominee for director to hold office until the 2021 Annual Meeting of Shareholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.
3.To conduct any other business properly brought before the meeting.
|
| 2017-04-19 |
股东大会：
将于2017-06-01召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s two nominees for director to hold office until the 2020 Annual Meeting of Shareholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017.
3.To conduct any other business properly brought before the meeting.
|
| 2016-04-28 |
股东大会：
将于2016-06-07召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s three nominees for director to hold office until the 2019 Annual Meeting of Shareholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2016.
3.To conduct any other business properly brought before the meeting.
|